Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FX Other monoclonal antibodies and antibody drug conjugates
L01FX26 Mirvetuximab soravtansine
D10954 Mirvetuximab soravtansine (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Anti-Microtubulars
Mirvetuximab Soravtansine
D10954 Mirvetuximab soravtansine (USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D10954 Mirvetuximab soravtansine
Target-based classification of drugs [BR:br08310]
Transporters
Other transporters
Others
FOLR1
D10954 Mirvetuximab soravtansine (USAN/INN) <US>
Not elsewhere classified
Cellular process
Cytoskeleton
TUBB
D10954 Mirvetuximab soravtansine (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10954
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10954
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10954
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10954
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10954
